The awarded research projects of Michiel Vermeulen, Jolanda de Vries, Gerty Schreibelt, Martijn Verdoes and colleagues will initiate new research lines and collaborations between various research groups. Amongst other things, these projects will work on improving immune therapies against cancer and the role of genes in ageing processes.
The, in total 12, awarded projects will jointly receive over nine million euros from this first round of the ZonMw Open Competition. This programme aims to create opportunities for outstanding curiosity-driven (groundbreaking) research. The funding enables excellent research groups to renew their research lines that contribute to health research. Another important requirement is that they realize new collaborations between various research groups.
Defining H3K9 methylation regulatory pathways in monocyte and macrophage function in cardiovascular disease
More information about this project will follow soon.
Jolanda de Vries, Gerty Schreibelt and Martijn Verdoes
Optimizing the design of dendritic cell vaccine immunotherapies
In recent years, vaccination has sprouted as an extremely promising new therapeutic strategy to combat cancer. Many clinical trials are based on the vaccination of cancer patients with peptides corresponding to cancer antigens with the aim of raising anti-cancer cytolytic T lymphocytes (CTL) responses. The efficacy of immune vaccines depends on how effective the peptide is cross-presented by dendritic cells (DCs) to activate CTLs. Goal of this project is to optimize the cross-presentation efficiency of cancer-specific MHC-I-binding epitopes by chemical modifications. We propose to unravel the cell-biological basis of cross-presentation of different antigen vaccine modalities by a combination of novel chemical approaches with state-of-the- art cell biology, microscopy and immunology. We envision that this study will lead to a universal strategy for designing optimal peptide-based anti-cancer vaccines. This novel directed approach will lead to a detailed understanding of CTL cross-priming and thereby allow for smart design strategies to optimize anti-cancer vaccination.
More information: link.
Related news items
Laurens Verscheijden awarded doctorate degree 'cum laude'19 January 2022
Laurens Verscheijden of the Department of Pharmacology and Toxicology, defended his PhD thesis, entitled "Mechanistic models for the prediction of brain drug exposure and response in the paediatric population: A virtual child reaching maturation.read more
Aerobe exercise has a positive effect on brain function in Parkinson's disease patients18 January 2022
Radboudumc researchers have shown that the brain function of patients with Parkinson's disease improved with regular exercise, which seems to strengthen the connections between different brain areas, while inhibiting brain shrinkage.read more
Last call for nominations for the RIHS Awards 2021 Deadline for submission is 25 January 202218 January 2022
RIHS researchers are invited to propose candidates for the RIHS PhD Award, the Societal Impact Award, the Science Award, the Supervisor of the Year Award, and the RIHS Patient Involvement Award.read more
Rogier Kievit and Geert Litjens both receive ERC Starting Grant of 1.5 million euros Board of Directors congratulates researchers on top grant13 January 2022
Researchers Rogier Kievit and Geert Litjens were today festively welcomed by the Board of Directors, because of the ERC Starting Grants they both received. With these European top grants, they can each design an ambitious research project and put together their own research group.read more
Improved AI will boost cancer research and cancer care Geert Litjens receives ERC Starting Grant13 January 2022
Geert Litjens from Radboud university medical center has received a European Research Council (ERC) Starting Grant.read more
Understanding fluctuation variation in cognitive abilities may provide insight into lifelong learning Rogier Kievit recieves ERC Starting Grant13 January 2022
Rogier Kievit from Radboud university medical center has received a European Research Council (ERC) Starting Grant.read more